November 8, 2022 - November 12, 2022
Boston, MA
Learn More

WuXi AppTec offers an end-to-end platform of immuno-oncology services to support drug discovery teams.  Stop by booth #230 to learn about our unrivalled portfolio of PDX, CDX, and syngeneic tumor models.  Our capabilities also include PBMC humanized mouse models, tissue-based biomarker analysis for checkpoint inhibitors, bispecific antibodies, and CAR-T/TCR-T cell therapy services.

Abstract ID: 237522
Engineered oncolytic viruses expressing immunomodulatory genes enhances in vitro anti-tumor cellular immune responses

Abstract ID: 214043
PD-1 blockade protein in 4th generation armored CAR-T cells enhances cytotoxicity effect with in vitro re-challenge system
Dr. Declan Ryan, Vice President of Business Development, WuXi AppTec
Yu Chen, Director of Business Development, WuXi AppTec
Mahnaz Arjomand, Executive Director of Business Development, WuXi AppTec
Dr. Luping Lin, Director, Discovery Biology, WuXi AppTec
Xiangnan Qiang, Associate Director, WuXi AppTec

Meet with Our Team